Abstract 1834P
Background
The first conversational AI Cancer mentor app was recently launched by Belong.life, a global oncology social network for cancer patients (pts) and caregivers. The app objectives are to provide uninterrupted support and guidance with empathetic, relevant information in cancer management. Belong’s unique and large datasets of pts to physicians and pts to pts interactions provide the basis for the AI platform, adding information from current guidelines, supplying solid up to date data with wide understanding of pts diverse cancer journeys.
Methods
Belong members enquiries, replied by the AI Cancer mentor were validated by 9 oncology experts in solid and haematological cancers, affiliated to various medical centres. 578 member enquiries coupled with the AI Cancer mentor replies, were randomly chosen and distributed according to cancer groups: Breast, Gastrointestinal, Pancreatic, Genitourinary, Musculoskeletal, Haematology and Radiation therapy. The oncologists assessed the AI mentor accuracy of recommendations by relevance and helpfulness, aligning them to evidence-based medicine and current international guidelines.
Results
527/578 (91.18%) AI Cancer mentor replies received a positive validation for their suitable and relevant recommendations. Conversely, 46/578 (7.96%) received a negative validation, while only 5/578 (0.86%) graded as not helpful. Minor variations were noticed in the cancer groups, with positive validations as follows: Genitourinary 100%, Breast 95.7%, Pancreatic 92%, Musculoskeletal 91.2%, Radiation therapy 88%, Gastrointestinal 86.4%, Haematological cancers 84%.
Conclusions
The reported accuracy (91.18%) on 578 pts enquiries and AI Cancer mentor replies, evaluated by a multi-disciplinary, multi-institutional oncologist group, are very promising, indicating that the Belong’s AI cancer mentor provides valuable and reliable recommendations. The findings offered insights into the AI mentor’s performance across a wide group of cancers. Based on this report, the addition of an AI mentor in cancer care, provides helpful, relevant guidance on pts diverse cancer journeys, while supporting oncologists in their pts management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
B. Haikin, D.A. Vorobiof: Financial Interests, Personal, Full or part-time Employment: Belong.life. All other authors have declared no conflicts of interest.
Resources from the same session
1906P - ESMO-ESTRO consensus recommendations regarding the safety of combining radiotherapy with targeted agents or immunotherapy
Presenter: Evert van Aken
Session: Poster session 12
1907P - Deployment of remote patient monitoring in older patients: A real-world experience from 2419 patients across 58 centres in France and Belgium
Presenter: Nicolas Bertrand
Session: Poster session 12
1908P - Grading the evidence for physical activity and all outcomes in cancer survivors: An umbrella review of more than 700 meta-analytic associations
Presenter: Panagiotis Filis
Session: Poster session 12
1909TiP - Home-based physical exercise during neoadjuvant treatment for early breast cancer patients (HoPEx-Breast): A pragmatic randomised controlled trial
Presenter: Rita Pichel
Session: Poster session 12
1943P - Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: A joint SITC and INMC effort
Presenter: Julie Deutsch
Session: Poster session 12
1944P - Super-enhancer driven NR3C1 expression promotes 5-FU resistance in gastric cancer
Presenter: Bingya Liu
Session: Poster session 12
Resources:
Abstract
1945P - Stroma-derived bIgH3 (βigH3/TGFBI) is the local mediator of pathological TGFβ activity in pancreatic cancer and a target to treat in patients with high fibrotic activity
Presenter: Morten Karsdal
Session: Poster session 12
1946P - SLC7A9 suppression increases chemosensitivity by inducing ferroptosis via inhibiting cystine transportation in gastric cancer
Presenter: Jianfang Li
Session: Poster session 12
Resources:
Abstract
1947P - Organoid establishment from multiple biological sources in biliopancreatic cancers
Presenter: Michele Zanoni
Session: Poster session 12
1948P - Analysis of cytokines, chemokines, and tumor-infiltrating lymphocytes as immunological markers predicting pathological complete response in triple-negative breast cancer: Exploratory analysis of the NACATRINE trial
Presenter: Ana Julia de Freitas
Session: Poster session 12